The 11th ISM Annual Meeting Targeting Microbiota 2024, organized on 14-15 October at Corinthia Palace Malta, have released their program covering microbiome advancements and their implications for health and disease. The ISM invited speakers to highlight their strategies and perspectives.
Credit: International Society of Microbiota (ISM)
The 11th ISM Annual Meeting Targeting Microbiota 2024, organized on 14-15 October at Corinthia Palace Malta, have released their program covering microbiome advancements and their implications for health and disease. The ISM invited speakers to highlight their strategies and perspectives.
How to avoid the “déjà vu” talks? The scientific committee will introduce novel approaches and groundbreaking research that push the boundaries of current knowledge, ensuring fresh perspectives and innovative solutions.
What New Perspectives Do Keynote Speakers Bring to ISM 2024?
1. Mzia Kutateladze, Director at G. Eliava Institute of Bacteriophages, Microbiology and Virology, Georgia
“Phage Therapy: A New Era of “Old” Concept for “Microbiome” Health“
Dr. Mzia Kutateladze’s insights into phage therapy will highlight a cutting-edge approach to manipulating the microbiome to combat numerous diseases and improve health outcomes. She will present a groundbreaking exploration of phage therapy targeting the gut and skin, covering the potential of bacteriophages to revolutionize clinical treatments and improve patient outcomes through precision microbiome modulation.
2. Marvin Edeas, from Institut Cochin, INSERM U1016, Université de Paris, France
“The Mystery of the Microbiome Genome: The Potential of 2 to 20 Million Microbial Genes to Transform Our Health”
Complementing this, Dr. Marvin Edeas’s exploration of the microbiome genome, containing an estimated 2 to 20 million genes, will delve into the vast genetic landscape of the human microbiome. His keynote will discuss the implications of this genetic diversity for human health, exploring how we might outsource more functions from our microbiome to our health. This involves understanding how these microbial genes interact with our own and how we can influence these interactions.
What’s on the Agenda?
Monday, October 14, 2024
Day one highlights the latest microbiota research, covering topics like phage therapy, and the gut microbiome’s role in obesity and diabetes. Discussions include microbiome signatures in irritable bowel syndrome and the influence of gut bacteria on heart health.
Keynote Speech: Phage Therapy: A New Era of “Old” Concept for “Microbiome” Health
Microbiota in Health & Disease: Advancements & Perspectives
- Martin Loessner from ETH Zurich will discuss the engineering of synthetic phages to target bacterial pathogens and re-balance the microbiome.
- Alan Walker, University of Aberdeen, United Kingdom, will address common misconceptions surrounding the human microbiome.
- Hiroshi Ohno, from RIKEN Center for Integrative Medical Sciences, Japan, will explore the role of gut microbiome in diseases like obesity and diabetes, presenting potential preventive measures.
- Simone Domenico Guglielmetti, from Università degli Studi di Milano-Bicocca, Italy, will delve into the gut microbiome signatures associated with irritable bowel syndrome.
- Patrick C. H. Hsieh, from Academia Sinica, Taiwan, will discuss the influence of gut microbiota on heart recovery post-heart attack, exploring potential therapeutic interventions.
- Justus Reunanen, from University of Oulu, Finland, will explore the role of microbiota-derived extracellular vesicles in maternal-fetal communication.
- Souhaila Al Khodor, from Sidra Medicine, Qatar, will discuss the intricate relationship between the oral-placental microbiome axis and preterm birth.
- Koen Venema, from Maastricht University, Netherlands, will provide insights into sophisticated in vitro models of the GI tract for studying the effects of probiotics and prebiotics.
- Christian Riedel, from University of Ulm, Germany, will explore the diverse applications of bacteriocins and propose solutions for their production and application.
Tuesday, October 15, 2024
Day 2 focuses on clinical applications, discussing strategies for targeting the microbiota and selecting probiotic strains. Topics include microbial phenotypes in obesity and microbiota-mitochondria interactions in kidney disease, providing valuable updates for improving human health.
Keynote Speech: The Mystery of the Microbiome Genome: The Potential of 2 to 20 Million Microbial Genes to Transform Our Health
Microbiome Medicine: Major Advances Towards Clinical Applications
- Koen Venema, from Maastricht University, Netherlands, will provide insights into the current state-of-the-art in targeting the microbiota for therapeutic purposes.
- Andreas Schwiertz, from Institute of Microecology, Germany, will discuss the selection criteria for probiotic strains and their associated health benefits.
- Rochellys Diaz Heijtz, from Karolinska Institutet, Sweden, will cover the impact of gut microbiota in early Life on neurodevelopmental outcomes.
- José Manuel Fernández-Real, representing Institut d’Investigació Biomèdica de Girona, Hospital Trueta de Girona, and University of Girona, Spain, will shed light on the gut brain axis & depression while focusing on the strategic role of dietary proline.
- Ellen Blaak, from Maastricht University, Netherlands, will explore the role of microbial phenotypes in obesity and its implications for precision nutrition.
- Pascale Vonaesch, from Lausanne University, Switzerland, will discuss the impact of targeting small intestinal microbiota on metabolism.
- Marvin Edeas, from Institut Cochin, INSERM U1016, Université de Paris, France, will explore the influence of microbiota-mitochondria interactions on kidney disease progression.
For more information, about Targeting Microbiota 2024 Conference, please visit: www.microbiota-ism.com.
Follow ISM:
LinkedIn – Facebook – Newsletters
